Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Alexion Pharmaceuticals & Minoryx Therapeutics to Present at SMi's Orphan Drugs & Rare DiseasesSMi Reports: Alexion Pharmaceuticals and Minoryx Therapeutics to deliver presentations at the 9th Annual Orphan Drugs and Rare Diseases Conference
By: SMi Group Ltd 
Orphan Drugs & Rare Diseases 2019 This year's Orphan Drugs and Rare Diseases Conference, returning for its 9th year to London this October, will tackle the main challenges facing the industry, and look at how commercialisation and patient access can be advanced. Recent success stories demonstrate the impressive progress made by the industry to tackle the difficult mission of commercialising drugs that rare disease patients desperately need. Here are a few recent achievements made by some of the companies speaking at the 2019 conference: This year's top 10 drug launches featured many rare disease treatments, with Alexion Pharmaceuticals' Soliris follow-up, Ultomiris, topping the list at number one, which received an early FDA approval ahead of its scheduled decision date (source: Fierce Pharma). Executive Director, Portfolio Products of Alexion Pharmaceuticals, Michael Page, will be chairing day one of the conference as well as presenting on an "Overview of Current Orphan Drug Regulation", focusing on: · Discussion on current state regulation of orphan drugs, and the level of scientific rigour needed for orphan drug approval (accepting small patient group studies and short studies) · Assessing the importance of clinical evidence during the launch of an orphan drug, considering the difficulty in planning and executing clinical trials for rare/ultra-rare diseases · Synopsis of the evidence requirements before and after the registration and open access to a new drugs Meanwhile, Minoryx Therapeutics, a clinical stage biotech company leading the development of new therapies for rare diseases, announced its first patient dosed in the FRAMES phase 2 trial in Friedreich's Ataxia (Source: Biospace). Based on preclinical studies, the drug showed impressive efficacy, increasing neuron survival, improving mitochondrial function and biogenesis, and restoring energy production. Chief Regulatory Office of Minoryx, Maria Pascual, will deliver a high-level presentation on "Technology and Orphan Drug Development" · Experiences and perspective on the various challenges in the development of orphan drugs and the available facilitating and accelerating toolbox · Analysing the challenges associated with the data sharing and analysis for rare disease research · Changes in market prospects for rare diseases following the improvement in efficiency of drug development Alexion and Minoryx are paving the way to success by repurposing existing drugs in order to treat rare diseases, which means fewer complex trials, less expenditure, and a quicker timeline. Hear from an unparalleled expert speaker line-up at this year's Orphan Drugs and Rare Diseases Conference. The brochure with full speaker line up is available to download online at https://www.smi- Plus, attendees will have the benefit of being able to take advantage of 5+ hours of dedicated networking with solution providers, biotechnology companies, clinical researchers, regulatory professionals and charity leaders. Register your place online at https://www.smi- For delegate enquiries, please contact Kieran Ronaldson on +44 (0)20 7827 6744 or kronaldson@smi- For sponsorship and exhibitor enquiries, please contact Alia Malick on on +44 (0) 207 827 6168 or amalick@smi- Orphan Drugs and Rare Diseases 2019 Conference: 15th – 16th October 2019 Workshop: 17th October 2019 London, UK #SMiOrphanDrugs ---- END ---- About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to- End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number